Translation and validation of Polish versions of the Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire

Kinga Maria Tyczyńska[1] ID ✉, Piotr Krzysztof Krajewski[2] ID , Daria Kuc[3] ID , Piotr Krawiec[4] , Piotr Wawryka[1] ID , Adam Zalewski[2] ID , Brygida Kwiatkowska[3] ID , Jacek Cezary Szepietowski[5,6] ID , Bogdan Piotr Batko[4] ID

[1]Department and Clinic of Rheumatology and Internal Diseases, Wroclaw Medical University, Poland
[2]University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, Poland
[3]Early Arthritis Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
[4]Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland
[5]Department of Dermato-Venereology, 4th Military Hospital, Wroclaw, Poland
[6]Faculty of Medicine, Wroclaw University of Science and Technology, Poland

Abstract

Introduction: Early detection of psoriatic arthritis (PsA) is critical to prevent joint damage and disability. The Psoriasis Epidemiology Screening Tool (PEST) and the Early Arthritis for Psoriatic Patients (EARP) questionnaire are established instruments for identifying PsA in patients with psoriasis. However, validated Polish versions were not available. This study aimed to translate and validate the Polish versions of both questionnaires.

Material and methods: The translation process followed international guidelines. Two independent forward translations from English to Polish were performed by translators (P.K.K., K.M.T.), and a unified version was established by a third consultant (J.C.S.). This was followed by two independent back translations from Polish into English (A.Z., P.W.) to ensure accuracy. The back translations were presented to the authors of the original questionnaires. Cognitive debriefing was conducted with eight patients diagnosed with PsA to enhance clarity and cultural relevance. The final Polish questionnaires were then administered to 45 adult patients diagnosed with PsA, as defined by the Classification Criteria for Psoriatic Arthritis, who were recruited from three clinical centers. Participants completed the questionnaires twice within a 3-to-5-day interval. The obtained data were subjected to statistical analysis.

Results: The Polish versions of PEST and EARP demonstrated adequate internal consistency, with Cronbach's α values of 0.712 for PEST and 0.771 for EARP. Test-retest reliability was robust, with intraclass correlation coefficient values of 0.731 and 0.730 for the respective questionnaires. No statistically significant differences were observed between the two assessments ($p > 0.05$). A limitation of this study is the absence of convergent validity, primarily due to the lack of other validated Polish screening instruments.

Conclusions: The validated Polish versions of the PEST and the EARP questionnaires are reliable instruments for screening PsA. Their implementation in clinical practice may facilitate early diagnosis and referral to rheumatology, thereby enhancing patient management in Poland.

Key words: psoriatic arthritis, psoriasis, surveys and questionnaires, mass screening.

Introduction

Psoriatic arthritis (PsA) is a chronic, immune-mediated disease characterized by musculoskeletal involvement, including arthritis, enthesitis, spondylitis, and dactylitis, which is commonly associated with psoriasis (PsO) [1]. Persistent inflammation may lead to joint destruction and disability, which might be prevented with early diagnosis and treatment [2]. Individuals with PsO who visit general practitioners or dermatologists may report joint-related symptoms. However, diagnosing PsA can be challenging for non-rheumatologists. This underscores the importance of having a reliable screening tool to identify patients who may require further evaluation by a rheumatologist. To facilitate earlier detection of PsA, several simple screening tools have been created.

The Psoriasis Epidemiology Screening Tool (PEST) is a self-administered questionnaire consisting of 5 items, complemented by a figure for patients to mark areas of concern. PEST demonstrates a sensitivity of 92% and a specificity of 78% in patients with PsO. Each item in the questionnaire has a "Yes" or "No" answer, scored as 1 and 0 points, respectively. A total score of 3 points or higher indicates a positive result and suggests the need for further rheumatological evaluation. Although the manikin does not contribute to the discriminative ability of the questionnaire, it enables the physician to quickly identify affected joints. The figure does not enhance the diagnostic accuracy of the questionnaire; however, it provides valuable information for clinicians to efficiently identify affected joints, thereby facilitating the referral process when indicated [3]. Another tool, designed for early detection of PsA, is Early Arthritis for Psoriatic Patients (EARP), a straightforward 10-item questionnaire with a sensitivity of 85% and a high specificity of 92%. The EARP questionnaire includes questions about joint pain, stiffness, swelling, lower back pain, and other related signs. Each question has a "Yes" or "No" answer, scored as 1 and 0, respectively. The total score is calculated by summing positive answers, with a score of 3 points or higher indicating the need for further rheumatological evaluation. For patients scoring below 3 points but with persistent or worsening symptoms, it is recommended to consider reevaluating with EARP or consulting a specialist [4]. Until now, none of these tools has been officially available to the Polish population. The objective of this study was to translate and further validate the PEST and EARP questionnaires, creating a Polish-language version as a screening tool for identifying individuals with PsA in the Polish population.

Material and methods

Translation and validation

The Polish translations of the EARP and PEST questionnaires were carried out according to the internatio-nal guidelines [5, 6]. Initially, two independent forward translations for each questionnaire were prepared (P.K.K., K.M.T.). Then, the final, unified version was created by a third, independent consultant (J.C.S.), a PsA expert fluent in both Polish and English, to resolve any discrepancies between the translations. The next step involved creating two separate back translations of the harmonized Polish versions of both questionnaires (A.Z., P.W.). None of the translators was familiar with the original versions of the questionnaires. These English versions were presented to a member of the original questionnaire development team, who accepted the translations without further modifications, ensuring the accuracy of the final Polish versions of the EARP and PEST questionnaires. Cognitive debriefing was conducted with eight participants, consisting of 4 females and 4 males diagnosed with PsA. Participants were asked to provide suggestions for improving the clarity and understandability of the questions and answer categories in both questionnaires. After the translation, Polish versions of the EARP and PEST questionnaires were validated as follows.

The Polish versions of the EARP and PEST questionnaires were distributed to 45 adult patients diagnosed with PsA according to the 2006 Classification Criteria for Psoriatic Arthritis. Data were collected from three different clinical centers – the Department of Rheumatology and Immunology in Krakow; the Department of Rheumatology and Systemic Connective Tissue Diseases in Warsaw; and the Department of Rheumatology and Internal Diseases in Wroclaw – with 15 patients from each center. The study group included 20 females and 25 males, 19 to 73 years (mean age: 49.16 ±12.62 years). All participants were asked to complete the Polish versions of the EARP and PEST questionnaires twice, with the second completion occurring 3–5 days after the first. This interval enables a similar clinical state to be maintained and is sufficiently long to prevent participants from recalling their previous responses.

Statistical analysis

The statistical analysis of the obtained data was conducted using IBM SPSS Statistics v. 26 (IBM Corp, USA). The internal consistency of both questionnaires was assessed with the Cronbach's α coefficient, where a coefficient of at least 0.7 is considered indicative of internal consistency [7]. The reproducibility (test-retest reliability) of each questionnaire was evaluated by comparing each patient's two sets of responses using the intraclass correlation coefficient (ICC). To demonstrate adequate reproducibility, the ICC, like the Cronbach's α coefficient, should also be at least 0.7 [8]. The correlation between individual items from the first and second completions was analyzed separately for each questionnaire using a Wilcoxon signed-rank test. The Spearman correlation

Table I. Psoriasis Epidemiology Screening Tool – reproducibility of the results

Item	1st assessment (points)	2nd assessment (points)	p
P1	1.04 ±0.208	1.04 ±0.208	1
P2	1.07 ±0.252	1.09 ±0.288	0.317
P3	1.29 ±0.458	1.29 ±0.458	1
P4	1.33 ±0.477	1.31 ±0.468	0.317
P5	1.24 ±0.435	1.29 ±0.458	0.157
P Total	4.02 ±0.988	3.98 ±0.988	0.257

Table II. Early Arthritis for Psoriatic Patients – reproducibility of the results

Item	1st assessment (points)	2nd assessment (points)	p
E2	1.33 ±0.477	1.31 ±0.468	0.564
E3	1.49 ±0.506	1.51 ±0.506	0.564
E4	1.49 ±0.506	1.49 ±0.506	1
E5	1.11 ±0.318	1.18 ±0.387	0.083
E6	1.33 ±0.477	1.38 ±0.490	0.157
E7	1.42 ±0.499	1.42 ±0.499	1
E8	1.78 ±0.420	1.73 ±0.477	0.157
E9	1.29 ±0.458	1.29 ±0.458	1
E10	1.36 ±0.484	1.29 ±0.458	0.257
E Total	6.33 ±2.558	6.38 ±2.794	0.317

Fig. 1. Psoriasis Epidemiology Screening Tool Total Score and Early Arthritis for Psoriatic Patients Total Score correlation.

coefficient was used for correlations between the validated questionnaires. A 2-sided p-value of ≤ 0.05 was statistically significant.

Bioethical standards

Due to the nature of this study, approval from the bioethics committee was not required.

Prior to the translation and validation process, permission was obtained from the original questionnaires' authors [3, 4].

Results

The analysis of internal consistency of the Polish language versions of PEST and EARP indicated that the individual items from the questionnaires were correlated with one another. Cronbach's α coefficient value for the PEST total score was 0.712, and for the EARP total score was 0.771, which indicated an adequate internal consistency of each of the translated questionnaires.

The reproducibility of the studied questionnaire, determined using the ICC, was 0.731 for PEST and 0.730 for EARP (Tables I, II). No statistically significant differences were found between the answers for each question obtained after completing the questionnaire twice (3–5 days' interval).

The correlation analysis indicates moderate to strong positive relationships between the total scores of PEST and EARP (Fig. 1), as well as between these scores and the number of affected joints (Figs. 2 and 3). Specifically, the PEST total score from the first assessment shows a moderate positive correlation with both the number of affected joints ($r = 0.606$, $p < 0.001$) (Fig. 2) and the EARP total score ($r = 0.530$, $p < 0.001$) (Fig. 1). Additionally, a strong positive correlation is observed between the number of affected joints and the EARP total score ($r = 0.640$, $p < 0.001$) (Fig. 3).

Fig. 2. Psoriasis Epidemiology Screening Tool Total Score and affected joints correlation.


Fig. 3. Early Arthritis for Psoriatic Patients Total Score and affected joints correlation.

The Polish validated versions of PEST and EARP are presented in Figures 4 and 5. The original versions are available in the supplementary file (Suppl. Figs. 1 and 2).

Discussion

Psoriatic arthritis is a chronic inflammatory condition characterized by joint damage and disability [1, 9]. Research indicates that up to 30% of individuals with PsO develop PsA, typically within 10 years of the initial appearance of skin symptoms. Studies suggest that between 5% and 15.5% of PsO patients may have undiagnosed PsA. Even a 6-month delay in diagnosis after symptom onset has been associated with joint damage and poorer long-term physical function [10].

A multidisciplinary approach involving primary care physicians, dermatologists, and rheumatologists is essential for improving the early detection and diagnosis of PsA [11, 12]. Factors such as the severity of PsO, specific locations of skin lesions (e.g., scalp, nails, intergluteal area), and the presence of certain biomarkers or genetic predispositions may indicate a higher risk of joint involvement [13–16].

To support earlier detection, several simple and validated screening tools have been developed, including the EARP questionnaire [4], the Psoriatic Arthritis Screening and Evaluation (PASE) tool [17], PEST [3], the Psoriatic Arthritis Uncluttered Screening Evaluation questionnaire [18], and the Toronto Psoriatic Arthritis Screen (ToPAS) [19]. Despite their demonstrated utility, these tools remain underutilized in clinical settings [20].

Experts emphasize the importance of early referral to rheumatologists for PsA patients. Approximately two-thirds of patients with PsA diagnosis present with at least one joint erosion at their first rheumatology consultation [20, 21]. Late referrals are associated with worse functional outcomes, as measured by Health Assessment Questionnaire scores [22]. Moreover, a pro-

active approach to managing newly diagnosed PsA, incorporating regular reviews and treatment adjustments every 4 weeks, has been shown to significantly improve joint health outcomes [23].

In 2021, Urruticoechea-Arana et al. [20] published a systematic review that, among other objectives, compiled studies comparing various early PsA screening tools within the same population. The study found that PEST and EARP demonstrated slightly better performance compared to other commonly used questionnaires, such as PASE and ToPAS [20]. Therefore, they were considered for the current project.

In 2024, Biln et al. [24] published the results of a study aimed at identifying existing triage approaches for referring patients with suspected inflammatory arthritis from primary care physicians to rheumatologists. Using a comprehensive search strategy across multiple international databases, the authors included 53 studies. They highlighted several tools – including the Early Inflammatory Arthritis Questionnaire, the Case Finding Axial Spondyloarthritis tool, and PEST – that have the potential to improve current referral processes [24].

Early Arthritis for Psoriatic Patients has been used in multiple languages, including Italian (authors of original questionnaire) [4], Thai [25], Japanese [26], Spanish [27], Hebrew [28], and Dutch [29]. Notably, the Japanese version [26] demonstrated very high sensitivity and specificity, both 97.2%, indicating excellent diagnostic accuracy. The Thai version of EARP [25] also showed good performance, with a sensitivity of 83% and specificity of 79.3%, making it effective in its target population. Similarly, PEST has been translated into Thai [25], Portuguese [30], Italian [31], Spanish [27], Hebrew [28], and Dutch [29]. As in the case of EARP, the process of translation and validation was not described in every case mentioned. The Portuguese and Thai versions reported high levels of internal consistency (Cronbach's α of 0.90) and good diagnostic performance. Sensitivity and specificity var-

PSORIASIS EPIDEMIOLOGY SCREENING TOOL – PEST
(polskie tłumaczenie kwestionariusza PEST – narzędzia do badań przesiewowych w kierunku łuszczycy stawowej u pacjentów chorujących na łuszczycę)

Imię i nazwisko:
Data:

Proszę odpowiedzieć na poniższe pytania, stawiając „X" odpowiednio w kolumnie „TAK" lub „NIE":

		TAK	NIE
1.	Czy kiedykolwiek miał Pan/i spuchnięty staw (lub stawy)?		
2.	Czy lekarz kiedykolwiek powiedział Panu/i, że ma Pan/i zapalenie stawów?		
3.	Czy Pana/i paznokcie u rąk lub nóg mają wgłębienia lub dziurki?		
4.	Czy miał/a Pan/i kiedykolwiek ból pięty?		
5.	Czy miał Pan/i kiedykolwiek całkowicie spuchnięty i bolesny palec u ręki lub u nogi bez wyraźnej przyczyny?		

Proszę zaznaczyć stawy, w których odczuwa Pan/i dyskomfort (np. sztywność, obrzęk, ból stawu):


Fig. 4. The Polish validated version of PEST.

Polish versions of the Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire

241

EARLY ARTHRITIS FOR PSORIATIC PATIENTS (EARP) QUESTIONNAIRE
(polskie tłumaczenie kwestionariusza EARP-10 – narzędzia do badań przesiewowych w kierunku wczesnej łuszczycy stawowej u pacjentów chorujących na łuszczycę)

Imię i nazwisko:
Data:

Proszę odpowiedzieć na poniższe pytania, stawiając „X" odpowiednio w kolumnie „TAK" lub „NIE":

		TAK	NIE
1.	Czy bolą Pana/ią stawy?		
2.	Czy w ciągu ostatnich 3 miesięcy zażywał Pan/i środki przeciwzapalne częściej niż dwa razy w tygodniu z powodu bólu stawów?		
3.	Czy budzi się Pan/i w nocy z powodu bólu dolnej części pleców?		
4.	Czy odczuwa Pan/i poranną sztywność rąk przez ponad 30 minut?		
5.	Czy bolą Pana/ią nadgarstki i palce?		
6.	Czy Pana/i nadgarstki i palce puchną?		
7.	Czy ból i opuchlizna któregoś palca utrzymuje się dłużej niż 3 dni?		
8.	Czy Pana/i ścięgno Achillesa puchnie?		
9.	Czy bolą Pana/ią stopy lub kostki?		
10.	Czy bolą Pana/ią łokcie lub biodra?		

Fig. 5. The Polish validated version of EARP.

ied across studies, with reported ranges of 72–92% and 78–89.7%, respectively. This variability highlights the importance of adapting the questionnaires to the linguistic and cultural nuances of each region [20].

Comparisons between EARP and PEST in the same populations revealed variable performance levels. For example, EARP often demonstrated higher sensitivity, making it suitable for identifying more cases of PsA, while PEST offered higher specificity, reducing the likelihood of false positives. Studies suggest that EARP may be better suited for populations with a higher prevalence of PsA, whereas PEST is advantageous in settings where over-referral needs to be minimized [20].

Our study presents the successful translation and validation of the Polish versions of the PEST and EARP questionnaires, offering effective and accessible screening options for PsA in Polish clinical settings. The findings confirm that the Polish versions of both questionnaires retain strong psychometric properties, demonstrating adequate reliability, validity, and reproducibility, which supports their potential use in routine screening for PsA among PsO patients.

Study limitations

Despite these promising results, the study has certain limitations such as absence of convergent validity, primarily due to the lack of other validated Polish screening instruments. Moreover, the sample size, while sufficient for initial validation, restricts the generalizability of the findings to broader and more diverse populations. Additionally, a longitudinal approach could provide insights into the predictive accuracy of PEST and EARP over time, offering further validation of their effectiveness in screening.

Conclusions

The Polish versions of the PEST and EARP questionnaires are reliable and validated tools for PsA screening, facilitating early referral to rheumatology and optimizing patient care outcomes. This study lays the groundwork for integrating these tools into routine dermatologic and general practice in Poland, fostering earlier diagnosis and improved management of PsA in individuals with PsO.

Disclosures

References

1. Azuaga AB, Ramirez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci 2023; 24: 4901, DOI: 10.3390/ijms24054901.
2. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med 2017; 376: 957–970, DOI: 10.1056/NEJMra1505557.
3. Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 2009; 27: 469–474.
4. Tinazzi I, Adami S, Zanolin EM, et al. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis. Rheumatology (Oxford) 2012; 51: 2058–2063, DOI: 10.1093/rheumatology/kes187.
5. Acquadro C, Conway K, Hareendran A, Aaronson N; European Regulatory Issues and Quality of Life Assessment (ERIQA) Group. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health 2008; 11: 509–521, DOI: 10.1111/j.1524-4733.2007.00292.x.
6. Zimba O, Gasparyan AY. Designing, conducting, and reporting survey studies: a primer for researchers. J Korean Med Sci 2023; 38: e403, DOI: 10.3346/jkms.2023.38.e403.
7. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334, DOI: /10.1007/BF02310555.
8. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86: 420–428, DOI: 10.1037//0033-2909.86.2.420.
9. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251–265.e19, DOI: 10.1016/j.jaad.2018.06.027.
10. Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 2010; 24: 548–554, DOI: 10.1111/j.1468-3083.2009.03463.x.
11. Betteridge N, Boehncke WH, Bundy C, et al. Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol 2016; 30: 576–585, DOI: 10.1111/jdv.13306.
12. Sanz Sanz J, Beltran E, Diaz-Miguel Perez MC, et al. Quality standard for the management of patients with psoriatic arthritis: QUANTUM Project. Reumatol Clin (Engl Ed) 2020; 16: 203–215, DOI: 10.1016/j.reuma.2018.06.011.
13. Chandran V, Cook RJ, Edwin J, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010; 49: 1399–1405, DOI: 10.1093/rheumatology/keq105.
14. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72: 736–740, DOI: 10.1136/annrheumdis-2012-201706.
15. Caputo V, Strafella C, Termine A, et al. Overview of the molecular determinants contributing to the expression of Psoriasis

and Psoriatic Arthritis phenotypes. J Cell Mol Med 2020; 24: 13554–13563, DOI: 10.1111/jcmm.15742.

16. Wittkowski KM, Leonardi C, Gottlieb A, et al. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One 2011; 6: e20279, DOI: 10.1371/journal.pone.0020279.

17. Husni ME, Meyer KH, Cohen DS, et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581–587, DOI: 10.1016/j.jaad.2007.04.001.

18. Audureau E, Roux F, Lons Danic D, et al. Psoriatic arthritis screening by the dermatologist: development and first validation of the 'PURE-4 scale'. J Eur Acad Dermatol Venereol 2018; 32: 1950–1953, DOI: 10.1111/jdv.14861.

19. Gladman DD, Schentag CT, Tom BD, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009; 68: 497–501, DOI: 10.1136/ard.2008.089441.

20. Urruticoechea-Arana A, Benavent D, León F, et al. Psoriatic arthritis screening: a systematic literature review and experts' recommendations. PLoS One 2021; 16: e0248571, DOI: 10.1371/journal.pone.0248571.

21. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med 1987; 62: 127–141.

22. Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2015; 74: 1045–1050, DOI: 10.1136/annrheumdis-2013-204858.

23. Coates LC, Mahmood F, Freeston J, et al. Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. Rheumatology (Oxford) 2020; 59: 807–810, DOI: 10.1093/rheumatology/kez369.

24. Biln NK, Bansback N, Shojania K, et al. A scoping review of triage approaches for the referral of patients with suspected inflammatory arthritis, from primary to rheumatology care. Rheumatol Int 2024; 44: 2279–2292, DOI: 10.1007/s00296-024-05575-8.

25. Chiowchanwisawakit P, Wattanamongkolsil L, Srinonprasert V, et al. Developing the Thai Siriraj Psoriatic Arthritis Screening Tool and validating the Thai Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire. Rheumatol Int 2016; 36: 1459–1468, DOI: 10.1007/s00296-016-3513-4.

26. Maejima H, Katayama C, Taniguchi T, et al. Japanese version of the early psoriatic arthritis screening questionnaire (EARP). J Dermatol 2016; 43: 385–388, DOI: 10.1111/1346-8138.13092.

27. Vidal D, Reina D, Martin JL, et al. PASE and EARP questionnaires for the identification of enthesitis, synovitis, and tenosynovitis in patients with psoriasis. Clin Rheumatol 2016; 35: 2463–2468, DOI: 10.1007/s10067-016-3392-9.

28. Haddad A, Feld J, Zisman D. The Performance of Psoriatic Arthritis Screening Questionnaires in Patients with Psoriasis. J Rheumatol 2019; 46: 1643–1645, DOI: 10.3899/jrheum.180939.

29. Karreman MC, Weel AEAM, van der Ven M, et al. Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. Rheumatology (Oxford) 2017; 56: 597–602, DOI: 10.1093/rheumatology/kew410.

30. Mazzotti NG, Palominos PE, Bredemeier M, et al. Cross-cultural validation and psychometric properties of the Brazilian Portuguese version of the Psoriasis Epidemiology Screening Tool (PEST-bp). Arch Dermatol Res 2020; 312: 197–206, DOI: 10.1007/s00403-019-02013-9.

31. Chimenti MS, Esposito M, Graceffa D, et al. PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. Ther Adv Chronic Dis 2019; 10: 2040622319847056, DOI: 10.1177/2040622319847056.